- Maastricht University Medical Centre Maastricht (MUMC+)
- Danish Technical University (DTU)
- MAASTRO Clinic (MC)
- KU Leuven (KUL)
- Universita' Cattolica S. Cuore, Roma (UCSC)
- Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL)
- Universitair Ziekenhuis Gent (UZG)
- Université catholique de Louvain (UCL)
- Centre Oscar Lambret (COL)
- Universitaets Klinikum Tuebingen (TUB)
- University College London Hospital (UCLH)
The University of Maastricht (UM) and the University Medical Center Maastricht (azM) work together under the umbrella organisation Maastricht UMC+, or Maastricht University Medical Center+. Maastricht UMC+ is the perfect partner for: health recovery, health preservation and health promotion. Quality, safety and patient focus are given the highest priority in everything we do.
Maastricht UMC+ has three mutually reinforcing core tasks:
- Patient care: We provide diagnostics and treatment, from basic care to top clinical and top referral care to the most complex patients;
- Research: We do scientific research, from fundamental to applied, that complements and contributes to the specializations within patient health care;
- Education and Training: We train new generations of doctors and researchers.
In addition to these three core tasks, we realize that creating value from knowledge is becoming increasingly important.
Of the eight Dutch university medical centers, the Maastricht UMC+ is the only one that is both a teaching and general hospital. This enables us to quickly implement research results into our patient care and use them for care improvement and innovation. Our service area as an academic healthcare institution stretches from South Limburg to South-East Brabant. MUMC+ is the major health care provider in the Limburg and Brabant area in the Netherlands. The Comprehensive Cancer Center Maastricht (CCCM), of MUMC+ offers not only state-of-the-art treatment to cancer patients, but is also leading the Comprehensive Cancer Center Maastricht (CCCM), which links the oncology units of the Limburg and Brabant area of the Netherlands to MUMC+. CCCM standardizes and optimizes the medical care of the cancer patients, develops and participates in multicentre clinical trials and is also involved in translational research. CCCM is also highly active in postgraduate training. Our Clinical Trial Unit offers a full range of services in phase I, II and III clinical trials.
The Technical University of Denmark is ranked as one of the foremost technical universities in Europe, continues to set new records in number of publication. Related to the life sciences field, DTU is focussed on approaching areas of medical biology with a strong technology focus. With the vision that new technologies are required to reveal the pathogenic mysteries behind yet untreatable diseases. DTU offer a strong technical environment and good administrative support, essential for the research output. DTU vet, section for Immunology and Vaccinology has specific focus on Immunology related to both human and veterinary health. The section is currently expanding to become and immunological hotspot in the Copenhagen area. It offers core facilities with state-of- the-art equipment.
The research proposed in this application will be performed within MAASTRO (Maastricht Radiation Oncology, see www.maastro.nl) which is embedded in the GROW research institute (School for Oncology and Developmental Biology) and the Faculty of Health Medicine and Life Sciences at Maastricht University Medical Centre (MUMC+). MAASTRO is an integrated institute combining a radiation oncology center with facilities for research laboratories and clinical research. One of the strategic highlights of MAASTRO is: Lung Cancer and Tumour Microenvironment. An important strategic goal is individualization of treatment for our patients (www.predictcancer.org). In order to reach this goal we have to be able to accurately assess risks and benefits associated with (chemo)radiation by analysing available patient data. Clinical patient and outcome data have therefore been recorded in an electronic patient database since 2005. PET/CT images are stored in a database, and blood samples are taken before radiotherapy in a standardized way and stored in the biobank of MUMC+.
The department of Radiation Oncology of the University Hospitals Leuven/ KU Leuven is involved in several clinical research programs focusing on optimization of radiation therapy treatment using biological image guided target delineation, response prediction, prognosis and therapeutic outcome. The main task will be to include and treat patients with lung cancer and oligometastases in this project. This will be done in the The Leuven Lung Cancer Group (LLCG). The LLCG is a world- wide recognised high-quality clinical and experimental hub in which innovative diagnosis and treatment was pioneered. The group has published over 500 Wi-papers, including practice-changing work in diagnosis and treatment, some published in top-journals such as the Journal of Clinical Oncology, Chest, Lancet and The New England Journal of Medicine. The LLCG includes specialists in pulmonology, respiratory oncology, surgery, nuclear medicine, radiology, radiation oncology, pathology and rehabilitation.
The “Università Cattolica del Sacro Cuore”, founded in 1921, is the most comprehensive and complete legally recognized university in Italy: it includes five campuses (Milano, Brescia, Piacenza-Cremona, Roma and Campobasso), 14 faculties, 52 three-year major tracks, 42 graduate level degrees, 1 four-years degree, over 100 master tracks, 53 specializations and 5 Postgraduate Schools. The extensive research program closely collaborates with 16 internal colleges, 62 departments and 93 research centers. Their common goal is the understanding and study of those topics that have proved vital to the well being of each human being: the new frontiers of economics, bioethics, environmental recuperation, developments in the judicial fields, family dynamics, major mass phenomena, the evolution of political systems, new horizons in medicine, the technological applications of physics and mathematics, and the most recent discoveries in environmental research. The Faculty of Medicine, established in Rome in 1961, is at present a world-class training ground for future leaders in medical research and practice - including every modern medical discipline as well as some of the most respected medical scholars all over the world. - public health, and biomedical science. In addition to the courses of Medicine & Surgery, Nursing sciences, Physiotherapy, Public health, bioethics biomedical science and a variety of other clinical subjects, a prestigious School of Health Management (ALTEMS) is held.
The School of Medicine plays a pivotal role in the Italian community through its teaching hospital Fondazione Policlinico Universitario Agostino Gemelli (www.policlinicogemelli.it), that, with 1400 beds and a turnover of 70.000 patients annually, is part of the National Health Service as a hospital of national relevance at high specialization. The University remises include the main hospital building (the "Polyclinic"), the Biological Institutes", the "Protected Health Residence", the combined "Institute of Infectious Diseases" and "Centre for the Medicine of Aging” and the “Centre for Animal Experimentation”. Advanced research infrastructures are available for researchers including a clinical trial centre, and all the necessary laboratories and equipment.
Radiological Sciences Center is made up of Radiology, Nuclear Medicine, Medical Physics and Radiation Therapy Unit.
The Oncology Area is made up of Radiotherapy Oncology, Haematology and Medical Oncology. The Radiation Therapy Unit provides a variety of services:
The Radiotherapy planning and delivery Unit is a combined day care and outpatient unit based on the second floor of the Polyclinic, where the radiotherapy treatment is indicated, according to the clinical recommendations, planned and delivered through the dedicated technology (3 machines and 1 computed tomography for planning). The decision is made on a patient-by- patient basis, realizing an individualized treatment plan.
One cancer wards (17 beds) where patient, undergoing to radiotherapy or combined treatments or to supportive/palliative care, are admitted.
A Day Care Unit to give chemotherapy or support drugs
A Brachitherapy and a Metabolic Radiotherapy Unit for thyroid cancer treatment
The School of Radiation Oncology plays a relevant role in Italy with a turnover of 2000 patients annually, 22 residents, 6 researches, 20 medical doctors, one chair of Day Care Unit, one chair of department.
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL) is an integrated comprehensive cancer centre, combining a hospital and research laboratories in one independent organisation. The hospital accommodates 180 beds, including in-patient units for combined modality treatments and pharmacokinetics, a large Radiotherapy department and outpatient clinics. The laboratory covers all major areas of cancer research and includes many programs translating basic research findings into improved clinical cancer prevention, diagnosis and therapy. Basic researchers focus on molecular events that direct cell division, survival, differentiation and migration. Cell biologists are supported by excellent core facilities. The preclinical activities are clustered in the recently established Mouse Cancer Clinic: a large facility for maintenance of mouse strains with expert biotechnical staff and up-to-date equipment, including bioluminescence cameras, SPECT-CT, MRI imaging and an image-guided micro beam mouse irradiator (www.nki.nl).
UZ Gent is one of the largest and most specialized hospitals in Flanders, delivering a full range of highly specialized, high-quality care. As a university center UZ Gent is also investing in scientific research and education, for which it operates in close collaboration with the Faculty of Medicine and Health Sciences of the Ghent University. Set in this environment, the Radiation Oncology Department of the University Hospital in Ghent is an academic radiotherapy department with a focus on radiation technology development. It pioneered the introduction of intensity-modulated radiotherapy (IMRT) in Belgium and beyond. Its research focus now has shifted towards other novel radiotherapy technologies such as stereotactic ablative radiotherapy (SABR), adaptive radiotherapy (ART) and dose-painting. Through collaboration with the Lab for Experimental Cancer Research, a specific interest exists for the mechanisms of metastatic tumour development and progression, hence the emphasis on developing new treatment modalities for oligometastatic disease. Operating on 4 linear accelerators and with a staff of 11 radiation oncologists and 10 physicists (part of which have a major research activity), it delivers about 1800 new radiation treatments a year. Of these, about one out of four are enrolled in clinical trials.
The Cliniques Universitaires Saint-Luc (CUSL - UCL) is one of the main academic hospitals of Brussels, and is currently treating the largest number of cancer patients in this region. CUSL has 3 main priorities: high quality care, education, and research in fundamental, translational and clinical fields.
In this spirit, the radiotherapy department of the CUSL has been focusing for many years on the development, implementation and validation of novel radiotherapy technologies, including tumour motion management strategies, image-guided radiation therapy, dose painting with molecular imaging and Stereotactic Ablative Radiation Therapy. Two out of the 5 radiation oncologists are half-time research, and supervise 4 PhD students in the field of image-guidance and high precision radiation delivery techniques. Amongst the on-going research projects, we are currently leading 3 phase II trials on SABR in liver and lung primary tumours.
Centre Oscar Lambret (COL) is a regional center in northern france (Lille) dedicated to the fight against cancer. They offer specialist care, teaching and research in oncology. In collaboration with industries or academic institutions, the radiotherapy department of Centre Oscar Lambret has managed more than 20 national and international cancer clinical trials with more than 10 in the field of new target drugs.
We are an academic tertiary care center treating 2500 new cancer patients per year (>45000 fractions). Our clinical and scientific expertise include a broad spectrum of modern cancer therapy including imaging and high-precision radiotherapy. Our department is partner of the CCC with its Lung Center and the Translational Unit Immunotherapy. A total of 4 Linacswith IMRT/IGRT equipment, 12 board certified radiation oncologists including three specialised in lung cancer, 30 RTTs and a trial unit with coordiantors and nurses are available.The department has 40 beds for in- patients and a day clinic for outpatient chemotherapy.
University College London Cancer Institute and the University College Hospital form a leading UK Comprehensive Cancer Centre, combining basic cancer biology and translational research with delivering excellent cancer care. The research proposed within this application will be provided through the Radiotherapy Department and the Clinical Research Facility with support from the UCL Cancer Institute. It was awarded status of CRUK UCL-Manchester Lung Centre of Excellence in 2014
The Radiotherapy department is situated in the basement of University College London Hospital. The Department treats approximately 1800 patients a year. The equipment consists of: 5 Varian Linear Accelerators (Linacs), 4 of which have volumetric arc therapy facility, 4 with on-board imaging facilities and all with MLC’s and Portal Imaging, CT Simulator with Advantage Sim software, Orthovoltage treatment unit, HDR Brachytherapy theatre. UCLH offers stereotactic radiotherapy for cranial malignancies and early primary thoracic malignancies and is currently extending this technique to the management of oligometastastic disease at other sites. We have a working partnership with HCA having shared use of TrueBeam Linear Accelerator. UCLH was selected to host one of two Proton Beam Facilities in the UK and is planned to be clinically functional by 2018.
The NIHR/Wellcome Clinical Research Facility is a state-of-the-art early phase trials unit dedicated to cancer drug development. Located on the ground floor of the University College Hospital, the unit provides twenty treatment spaces, clinic rooms, a pharmacy dispensary and a GCLP sample handling laboratory. A broad portfolio of academic and commercially sponsored early phase clinical trials are undertaken by specialist clinical staff, including first-in-man as well as tumour specific phase I and II trials.
University College London (UCL) is one of the world’s leading universities and is renowned for its outstanding research and teaching. The university won the largest funding allocation from UK research councils in 2013. The UCL Cancer Institute is the hub for cancer research at UCL. The Institute is structured as five Departments (Oncology, Haematology, Pathology, Cancer Biology and the CR-UK UCL Clinical Trials Centre). It has a GCLP facility which contains a large assay lab for pharmacokinetic (PK) and pharmacodynamics studies, a lab for handling radioactive trial samples, a separate PCR lab, a monitored sample storage area, a microscope room and a clinical sample-handling lab which is linked to the Clinical Research Facility.